Bristol Sprycel Receives Broad Committee Support For Leukemia Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee votes unanimously in favor of dasatinib approval for all phases of Gleevec-resistant or intolerant CML.